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Recent outbreaks of bluetongue virus (BTV) serotypes 2 and 8 in many European countries 
provided an opportunity to investigate the possibility of improving the safety of the modified 
live vaccines administered mainly in South Africa. Modified live vaccines (MLV) released at 
a titre of 5 x 104 PFU/mL, raised concerns and prompted the need to determine the minimum 
titre which will still be protective and also safe. The BTVserotypes 2 and 8 vaccines were 
produced at the following titres: 102 PFU/mL, 103 PFU/mL and 104 PFU/mL, and were injected 
into 24 sheep which were then monitored. Blood was collected on days 0, 3, 6, 9, 12, 15, 18, 21, 
25, 28 and 4 months post vaccination, for seroconversion and viraemia studies. These sheep 
were later challenged at 4 months post vaccination using BTV infected cell culture material, 
they were then observed and bled and again tested for viraemia. There was no viraemia post 
vaccination, however, a febrile reaction did occur and seroconversion was demonstrated at 
low titres for both BTV 2 and 8. Although viraemia was demonstrated post challenge, sheep 
vaccinated with the low titre BTV 2 vaccine showed more than a 90% protection index at a 
lower titre of 103 PFU/mL, compared with BTV 8 that showed a protection index above 90% 
at all the titres used It is recommended that for BTV 2 vaccine, sheep should be vaccinated at 
a titre of 103 PFU/mL and at a titre of 102 PFU/mL with BTV 8 vaccine. 
© 2012. The Authors.
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Bluetongue (BT) is a non-contagious, insect-transmitted disease that infects certain domestic 
and wild ruminants that is caused by the bluetongue virus (BTV)1. Bluetongue viruses share a 
common group-specific antigen but are distinguishable on the basis of their serotype-specific 
antigen by using an in vitro virus serum neutralising assay (SNT). In the late 1960’s Howell applied 
this test in order to antigenically group 22 strains of bluetongue virus into 12 serotypes.2 Later 
other serotypes were identified and, to date, 26 known serotypes of BTV have been described 
worldwide.3,4 Twenty two of these serotypes are known to occur in South Africa (SA)5 of which 
15 are considered to be pathogenic to sheep.6,7 This disease is endemic in SA and Africa and since 
1999 BTV serotypes 2, 4, 6, 8, 9 and 16 have also been prevalent in Europe.3,8,9
Bluetongue virus can infect a wide host range, and because of this the different BTV serotypes and 
the role played by Culicoides spp. as vector, the eradication of this disease in endemic areas such 
as in SA would be difficult to achieve.6 In countries endemically infected with BTV, vaccination 
has proved the most effective and practical method implemented to reduce the spread of this 
disease.5,6,7,10 The economic impact of using other methods of control, such as slaughter, has 
led most countries to consider vaccination as the best tool available to control the spread of the 
disease.
Different types of vaccines have been developed to prevent BTV infection of ruminants. These 
include: modified live vaccines (MLV), inactivated whole (killed) virus preparations11,12 and 
virus like particles (VLPs). The latter allows the co-expression of three, four or five BTV genes 
from a single recombinant vector like the baculovirus multigene expression vector system. Other 
vector systems include vaccinia-, capripox- or canarypox viruses.13,14,15 Only MLV and inactivated 
vaccines are commercially available and have been administered in recent years.
An attenuated BTV blood vaccine, developed after serial passage in sheep, has been administered 
for almost 40 years.1,7 Subsequently, other serotypes of BTV were identified in outbreaks and, 
thus, a quadrivalent vaccine was developed in the early 1950’s.16,17 Further attenuation of the 
vaccine strains was achieved through serial passage of the BTV in embryonated chicken eggs and 
tissue culture aided by plaque purification of the virus.6,18 Modified live attenuated vaccines are 
easy and economical to produce, administered once and have been administered successfully for 
50 years.6,14 These vaccines replicate in the host without causing significant adverse clinical effects, 
and provide protection against challenge with virulent virus of the same serotype. 8,18,19,20,21,22 
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They are able to elicit both cellular and humoral immune 
responses, which are able to protect sheep against BT.23,24
Millions of doses of MLV are issued annually in South 
Africa to vaccinate sheep. Since 2000 Onderstepoort 
Biological Products (OBP) has also sold several million 
doses of monovalent BTV vaccines to different European 
countries.25,26,27 Currently all the serotypes in the cell culture 
adapted vaccine are released at a titre of 5 x 104 PFU/mL. 
However, concerns were regularly raised about the long 
duration of viraemia that may sometimes occur after 
vaccination, especially in merino sheep.28,29 This prompted 
the need to investigate the possibility of producing low titre 
BTV 2 and 8 vaccines which would still be protective, more 
economical and without severe side effects. 
Materials and methods
Animals 
The experiment was conducted at OBP Ltd in SA (25°29’S, 
28°.11 E, 1219 m a.s.1.). A total of 28 merino sheep that tested 
negative for antibodies to BTV (Indirect ELISA, Agriculture 
Research Council, Onderstepoort Research Institute [ARC-
OVI]) were selected and ranged in age from 9–12 months. The 
sheep were kept in an insect free isolation stable, were fed 
daily according to a random schedule and had continuous 
access to clean water. 
Vaccine development
Vaccines for BTV serotypes 2 and 8 were developed from 
field isolates obtained in SA and isolated at the ARC-OVI.
Production of the vaccines was implemented according to 
the current Standard operating procedure (SOP) of OBP 
(proprietary information). Prior to production, the identity 
of the working seed virus was firstly confirmed at the 
Biochemistry Section of the ARC-OVI using the SNT and a 
reverse transcriptase polymerase chain reaction (RT-PCR). 
Viruses were grown on baby hamster kidney cells and titres 
post freeze drying were 1.17 x105 PFU/mL for BTV 2 and 
1.17 x 106 PFU/mL for BTV 8. Prior to injecting sheep, the 
freeze dried material was reconstituted with sterile water 
and diluted further to obtain 102, 103 and 104 PFU/mL titres 
for both serotypes.
Inoculation of sheep
Vaccines were injected into 12 sheep per serotype and 
subdivided to 4 sheep per titre. A total of 24 sheep were 
vaccinated using 1 mL of vaccine and injected subcutaneously 
on the inner side of the thigh. A positive control, which was 
not vaccinated but was challenged and a negative control, 
which was not vaccinated and not challenged for each BTV 
serotype, was included. The sheep were clinically monitored 
post vaccination, and temperature readings were recorded 
for 14 days. The sheep were post bled using 10 mL vacu-
tubes containing lithium heparin as an anticoagulant and 
10 mL vacu-tube for serum, without an anticoagulant. Blood 
was collected on days 0, 3, 6, 9, 12, 15, 18, 21, 25 and 4 weeks 
and also 4 months post vaccination. Heparin blood was 
tested for viraemia and the serum for neutralising antibodies 
indicating seroconversion. 
Four months post vaccination, both heparin blood and serum 
were collected from the controls and vaccinated sheep, 
and, following this, the sheep were challenged (except the 
negative control sheep) with the homologous BTV serotype. 
They were then clinically monitored, temperature reactions 
were recorded for 14 days post challenge and were scored 
using the method of Huismans, Van der Walt, Cloete and 
Erasmus (1987).30 Blood was collected in heparin tubes on 
days 0, 3, 6, 9, 12, 15, 18, 21, 25 and 28 post challenge. 
Challenge material preparation
The bluetongue virus serotype 2 challenge material was 
obtained from the ARC-OVI collection whilst serotype 8 
was an isolate, BTV 8(G) 5/10A 2006/01KC 3BHK, that 
was obtained from the Institute for Animal Health (IAH) 
Pirbright, UK. The challenge material was prepared from 
cell cultures in which Vero cells were infected with infected 
sheep blood, observed for cytopathic effect (CPE) and the 
titre determined by viral plague assay and adjusted to a titre 
of 1x106 PFU/mL.
Viraemia testing 
Every 3rd day post vaccination and post challenge, 5 mL 
– 10 mL heparin blood was collected for virus isolation. 
The method applied was according to the SOP of OBP, as 
described in the OIE Terrestrial Manual 200831 and also as 
described by Clavijo, Hecket, Dulac and Afshar (2000).32 
Blood was considered negative for viraemia when no CPE 
was evident, even after the blind passage of the supernatant. 
Samples that showed CPE were further titrated on confluent 
Vero cells in 6–well plates to confirm results. 
Serological assays
Pre-vaccination serum was collected and tested for the 
presence of antibodies to BTV. Post vaccination serum was 
collected and tested for seroconversion and to quantify the 
level of antibodies post vaccination. Serum samples were 
collected on days 0, 3, 6, 9, 12, 15, 18, 21, 28 and four months 
post vaccination and tested using a commercially available 
competitive ELISA (VMRD, Inc.). Serum samples collected 
4 weeks and also 4 months post vaccination were tested by 
introducing the SNT on Vero cells in 96–well plates.31
Quality control and percentage protection index 
determination
Tests were conducted to confirm the titres of the freeze 
dried vaccine, the safety in laboratory animals and for 
sterility to confirm the absence of other organisms. All were 
performed as described in the OIE Terrestrial Manual.31,33 
The determination of the clinical reaction index (CRI) and 
the percentage protection index were calculated using the 
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method described by Huismans, Van der Walt, Cloete and 
Erasmus (1987).30
Ethical considerations
Vaccinated sheep showed a rise in temperature but no 
clinical disease. Some of the challenged sheep showed a rise 
in temperature but no clinical disease. One of the positive 
control sheep (challenged but not vaccinated) died 8 dpi. 
Results
Temperature reactions post vaccination 
Bluetongue virus serotype 2
Sheep vaccinated with the BTV 2 vaccine titre of 102 PFU/mL 
had pyrexia from day 7 to 9. All sheep vaccinated with BTV 
2 vaccine titre of 103 PFU/mL had pyrexia from day 5 to 7 
and also on days 11 to 13. Two sheep had high temperature 
reactions of 41 °C and 40.7 °C, respectively. Three sheep 
vaccinated with the high titre BTV 2 vaccine (104 PFU/mL) 
had pyrexia from day 6 to 8 on different days. 
Bluetongue virus serotype 8
All sheep vaccinated with the low titre BTV 8 (102 PFU/mL) 
vaccine had pyrexia on different days (5, 7 and 8). Additionally, 
those vaccinated with 103 PFU/mL had pyrexia on different 
days from day 5 to 8, however, one sheep reacted only on day 
6. The same reaction was seen in sheep vaccinated with high 
titre vaccine pyrexia, on days 6, 7 and 9. The temperature of 
the negative control was normal. 
Viraemia post vaccination
No viraemia was detected in any of the sheep post vaccination. 
Temperature reactions post challenge 
Bluetongue virus serotype 2
Three sheep vaccinated with the BTV 2 vaccine titre of 
102 PFU/mL, and challenged with the BTV 2 cell culture 
material, had pyrexia from day 1 and again on day 3 to 4 post 
challenge. Only one sheep, vaccinated with BTV 2 vaccine 
(103 PFU/mL), had pyrexia from day 2 to 6 post challenge. 
There was no pyrexia post challenge in sheep vaccinated 
with the high titer vaccine (104 PFU/mL), except the positive 
control sheep which had pyrexia from day 3 to 5 before it 
died on day 8.
Bluetongue virus serotype 8
Two sheep vaccinated with low titre BTV 8 vaccines 
(102 PFU/mL and 102 PFU/mL) had pyrexia on day 1 and 4 
after challenge. The sheep vaccinated with the high titre vaccine 
(104 PFU/mL) did not demonstrate any abnormal reactions, 
except the positive control sheep that had pyrexia from day 6–10. 
Viraemia post challenge 
Viraemia was detected in two sheep post challenge, at 
4 months post vaccination with both low titre BTV 2 vaccines 
(102 PFU/mL and 103 PFU/mL). Only one sheep showed 
viraemia, of those vaccinated with the high titre vaccine 
(104 PFU/mL). Viraemia was not detected in sheep challenged 
with BTV 8 in all three vaccinated groups.
Seroconversion
Bluetongue virus serotype 2
The sheep vaccinated with the low titre vaccine (102 PFU/mL 
and 103 PFU/mL) were seropositive on ELISA by day 21 post 
vaccination, and showed varied neutralisation titres of 1:16 
to 1:64 within 4 weeks post vaccination. Similar titres were 
observed at 4 months post vaccination. Those vaccinated 
with high titre vaccine also had neutralising titres within 
4 weeks and also 4 months post vaccination (Table 1). 
Bluetongue virus serotype 8
Two sheep seroconverted on day 9 post vaccination, whilst 
one sheep did not demonstrate detectable antibodies, even 
4 weeks post vaccination. However, all sheep had neutralising 
antibody titres above 1:16 at 4 months post vaccination 
(Table 2). 
TABLE 1: Seroconversion of sheep vaccinated with different titres of bluetongue virus serotype 2 vaccines.
Animal number Titres (PFU/mL) ELISA results (days post vaccination)  SNT titres
0 3 9 15 21  4 weeks 4 months
30 102 - - - - - < 1:4 0.08611
149 102 - - - + + 0.08611 0.08611
126 102 - - - - + 01:16 01:04
122 102 - - - + + 01:04 01:04
17 103 - - + + 01:32 01:32
125 103 - - - + + 0.08611 0.08611
38 103 - - - + 01:32 01:16
140 103 - - - + + 01:32 01:16
104 104 - - + - + 01:16 01:04
57 104 - - - - + 01:04 01:16
56 104 - - + + + 01:04 01:16
52 104 - - - + + 01:04 01:32
132 Negative control - - - - -  < 1:4 < 1:4
SNT, serum neutralisation test.
-, negative ; +, positive.
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Percentage protection index
Bluetongue virus serotype 2
At four months post challenge the sheep vaccinated with 
the low titre vaccine (102 PFU/mL) had 72% protection 
and two sheep had very high clinical reaction indexes. The 
positive control sheep had a high CRI and died on day 8 post 
challenge (Table 3). The presence of BTV 2 was confirmed by 
viral isolation.
Bluetongue virus serotype 8
All sheep vaccinated with low titre vaccine (102 PFU/mL and 
103 PFU/mL), and challenged with BTV 8, showed protection 
of 100% and 90.75%, respectively. The sheep vaccinated with 
the high titre vaccine had a 100% protection level (Table 4). 
Trustworthiness
The relevant controls were used during the vaccination 
and challenge of the sheep as well as in all laboratory tests 
performed. Validated standard operating procedures were 
followed in the laboratory. Results obtained are trustworthy. 
Discussion
In BT endemic areas, such as SA, the BTV MLV is 
predominantly applied to control BT disease in sheep,8,10 and 
this vaccine has successfully played a major role in controlling 
the spread of the virus in Europe.5,10,25 Virus titres induced by 
BTV MLV should be kept to an absolute minimum especially 
if transmission by vectors of viruses, included in the vaccine, 
is a concern.8 This is because the complex interaction of the 
different serotypes of BTV, Culicoides vectors and animal 
hosts in the life cycle of the virus.
The existence of at least 22 serotypes of BTV’s in SA and the 
presence of vectors that can transmit the disease, to different 
susceptible hosts, make the administration of BTV MLV 
economical for sheep farmers. However, the European Union 
has decided not to administer BTV MLV on the grounds of 
various concerns. These include the possible reassortment of 
vaccine viruses with circulating field strains and the possible 
reversion to virulence,34,35,36 the transmission of these viruses by 
vectors and the lack of a DIVA test for these vaccines.3,27 Another 
concern is the presence of a long duration viraemia when BTV 
MLV, with titres of or above 104 PFU/mL, are administered. 
It is also at this titre that susceptible sheep show clinical signs 
and suffer abortions.6,22 The administration of BTV MLV in 
Europe has, therefore, created concern and the need has arisen 
to investigate the use of reduced titres of 102 PFU/mL and 
103 PFU/mL in the vaccine for administration in sheep.
TABLE 2: Seroconversion of sheep vaccinated with different titres of bluetongue virus serotype 8 vaccines.
Animal number Titres (PFU/mL) ELISA titres (days post vaccination) SNT titres
0 3 9 15 21 4 weeks 4 months
114 102 - - - + + nd 1:2048
118 102 - - + + + nd 1:16
64 102 - - + - + nd 1:512
45 102 - - + + + nd 1:4096
44 103 - - - + + nd 1:1024
35 103 - - + + + nd 1:32
76 103 - - - + + nd 1:572
1 103 - - - - - nd 1:128
5 104 - - + + + nd 1:512
41 104 - - - + + nd 1:256
82 104 - - + + + nd 1:64
127 104 - - + + + nd 1:64
147 Control - - - - - < 1:4 < 1:4
nd, not done; SNT, serum neutralisation test.
-, negative ; +, positive.
TABLE 3: Clinical reaction and percentage protection index for bluetongue virus 
serotype 2 vaccine at different titres challenged at 4 months post vaccination.
Animal number Titres (PFU/mL) CRI Average (%)












59 Positive control 10 -
CRI, clinical reaction index. 
TABLE 4: Clinical reaction and percentage protection index of sheep vaccinated 
with bluetongue virus serotype 8 and challenged at 4 months post vaccination.
Animal number Titres PFU /mL CRI Protection (%) Average (%)
114 102 0 100 100
118 102 0 100
64 102 0 100
45 102 0 100
44 103 0 100 90.75
35 103 0 100
76 103 0 100
1 103 2 100
5 104 0 100 100
41 104 0 100
82 104 0 100
127 104 0 100
147 Positive control 5.5 - -
CRI, clinical reaction index.
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Titres of 104 PFU/mL, 103 PFU/mL and 102 PFU/mL were 
chosen to be tested as a dosage to be included in vaccines of 
BTV MLV. In this study there was no local or systemic reaction 
post vaccination and this confirms the results obtained by 
Hammoumi, Bréard and Sailleau (2003).37 However, transient 
fever was seen in this study within the first 14 days post 
vaccination which lasted only one to two days. Although 
viraemia could not be detected post vaccination, temperature 
reactions could be demonstrated and this corresponds with 
what has been indicated by Hammoumi et al., (2003) and 
Hunter and Modumo (2000),20,37and this also confirms the 
results obtained by Dungu, Gerdes and Smit (2004).5 
Cell culture material, and not blood, was selected as challenge 
material. From previous experience it was noted that the 
reaction to this in sheep is either late or poor when blood was 
used, as compared with cell culture material.8,38 The reason 
for this might be that BTV is a cell-associated virus and 
binds mainly to red blood cells, platelets and mononuclear 
cells.29,39,40 It is, however, important to realise that cell culture 
generated material might lead to the attenuation of the virus, 
which includes changes in virulence and antigenicity.8,36 
Blood-cultured material should, therefore, rather be applied 
as challenge material. 
Three sheep vaccinated with low titre 102 PFU/mL BTV 2 
had higher temperature reactions, above 40.5 °C – 41.5 °C, 
within the first 14 days post challenge, for 3–4 days. The same 
result was also seen in sheep vaccinated with low titre BTV 
8 vaccine.
Viraemia was detected post challenge with BTV 2, except with 
the high titre 104 PFU/mL BTV 2 vaccine, and no viraemia 
was detected using the three different vaccines for BTV 8. 
The reason for this might be that the cell culture material 
for BTV 2 was highly virulent, as the positive control died. 
It was also interesting to note that four sheep demonstrated 
both viraemia and seroconversion within the same period 
of 21 days. This might be attributed to the close association 
of BTV to cells which protect the virus from circulating 
antibodies.27,40 It was noted previously that a strong antibody 
response correlates with the virus circulating and replicating 
in the host body and, thus, with the possibility of viraemia.8
Although the BTV 2 low titre vaccine (102 PFU/mL) gave 
a protection index lower than 90%, the vaccine was able to 
protect the sheep from this clinical disease, especially when 
it is noted that the positive control sheep died. This confirms 
what was previously described, that BTV MLV offers 90.5% 
protection against clinical disease.10,18,20,25 There was also a 
good correlation between seroconversion and the protection 
index of sheep vaccinated with BTV 8 vaccines. The 
protection index of sheep vaccinated with BTV 8 was above 
90% at all titres. It should also be noted that the positive 
control of sheep challenged with BTV 2 had a far higher 
CRI (10) compared with the vaccinated group. The results also 
confirm that BTV 2 challenge material was more pathogenic 
than BTV 8 challenge material if comparison is made of the 
two viruses (Tables 3 and 4). 
It was clearly shown in this study that sheep vaccinated with 
the BTV 2 and 8 vaccines reacted differently. This confirms 
the results obtained by Howell (1969),18 that each BTV 
serotype reacts differently and their immunogenic potential 
differs from serotype to serotype. 
Although at a low titre (102 PFU/mL) BTV 2 vaccine offers 
protection against severe clinical disease, it is recommended 
to release the vaccine at a titre of 103 PFU/mL. The 
bluetongue virus serotype 8 can, however, be administered 
at the low titre of 102 PFU/mL. This study confirms that low 
titre BTV 2 and 8 vaccines are both immunogenic, and it is 
recommended that during production and release of multi 
serotype BTV vaccines, specific serotype titres should be 
considered rather than the average of all titres in a batch, as 
is currently practiced. 
More work remains to be undertaken to quantify the duration 
and level of viraemia post vaccination and post challenge, 
especially when low titres of virus are administered. Low 
titre vaccines should also be tested when included in a 
polyvalent format, as opposed to monovalent vaccines, 
as was done in this study. The response of indigenous 
European sheep breeds, different from those in SA, to low 
titre BTV vaccines should be assessed. To evaluate this, 
other diagnostic tools, like PCR, should also be used. It will 
additionally be important to investigate and assess the cost 
benefit of using both polyvalent and movalent low titre 
modified live attenuated BTV vaccines, and compare the risk 
factors associated with their use in sheep. 
Conclusion
Although viraemia was demonstrated post challenge, sheep 
vaccinated with the low titre BTV 2 vaccine showed more 
than a 90% protection index at a lower titre of 103 PFU/mL, 
compared with BTV 8 that showed a protection index above 
90% at all the titres used. It is therefore recommended that 
for BTV 2 vaccine, sheep should be vaccinated at a titre of 
103 PFU/mL and at a titre of 102 PFU/mL with BTV 8 vaccine. 
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